Cissus quadrangularis for Health & Longevity - Quick Reference Sheet

Cissus quadrangularis for Health & Longevity

Created on 09/27/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / GPT 6 – Audit

Cissus quadrangularis is a traditional medicinal plant used in supplements for bones, joints, and weight control. Local bone formation and joint comfort show limited positive signals; weight, blood sugar, and cholesterol findings conflict. Benefits depend on the preparation. Short studies leave long-term safety uncertain. Evidence does not establish reliable tissue repair, preventive bone strengthening, or longer healthy life. (Full Review)

Protocol

Metabolic studies
CQR-300: 300 mg/day
Once before breakfast or 150 mg twice daily before meals; 6–16 weeks. Extract-specific research regimens.
Joint-symptom study
3,200 mg/day orally
8 weeks in trained men; uncontrolled. No optimal dose or validated escalation schedule.
Bone studies
Dental: 500 mg/day
6 weeks. Postmenopausal study: 1.2 or 1.6 g/day for 24 weeks, without bone-density advantage.
Time to effect
Local bone formation during dental reconstruction
6 months after implantation
Greater local density and maturation; no established fracture prevention.
Joint pain and function
8 weeks
Improved symptoms in an uncontrolled exercise study.
Weight and body-fat reduction
6–16 weeks
Metabolic study duration; findings conflict across controlled studies.

Benefits

Contraindications
  • Prior allergic reaction or suspected Cissus-associated platelet decline
  • Pregnancy, breastfeeding, or childhood
  • Organ-transplant recipients using immunosuppression (particularly with unexplained low platelets; azathioprine, prednisolone)
  • Active bleeding or unexplained thrombocytopenia (low platelets; no Cissus-specific safe cutoff)
Key Interactions
  • Glucose-lowering drugs (insulin; sulfonylureas: glipizide, glimepiride; metformin, semaglutide, sitagliptin combinations untested)
  • Bleeding-related medicines (warfarin, apixaban; aspirin, ibuprofen)
  • Sedating substances (diazepam; diphenhydramine, alcohol, valerian; theoretical)
  • Glucose-lowering supplements (berberine, bitter melon, chromium; fasting, calorie restriction, prolonged exercise)
  • Serotonin-related agents (sertraline, fluoxetine; tramadol, 5-hydroxytryptophan; theoretical concern)
  • Surgery (two-week interruption: conservative convention, not an experimentally validated interval)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Digestive and oral discomfort; Headache, dizziness, and sleep disturbance; Warm sensations; Low platelet count; Uncertain kidney-marker changes
  • Speculative: Excess glucose lowering; Hormonal or reproductive effects; Sedation and impaired coordination

Monitoring

Marker Target Why
Weight and waistNo established Cissus target; personal baselineBody composition goal
Fasting glucoseNo Cissus-specific optimum; <70 mg/dL: safety triggerGlucose response and safety
Lipid profileNo established Cissus-specific functional range; baseline / individualized prevention targetClaimed lipid benefit
Blood pressureNo established Cissus-specific optimal range; baseline / individual targetClaimed pressure benefit
Platelet countNo established Cissus optimum; baseline / unexplained fallsBleeding signal
Creatinine and kidney filtration estimateNo established Cissus target; personal baselineUnexplained kidney-marker changes
Liver enzymes and bilirubinNo established Cissus-specific optimum; baseline / laboratory rangeContextual safety assessment
Bone densityNo established Cissus target; clinically indicated change beyond measurement errorEstablished bone-health concerns

Cadence: Illustrative: baseline; tolerability at 1–2 weeks; outcomes and justified repeat laboratory tests at 8–12 weeks, earlier for symptoms or abnormal results. Safety tests are context-dependent; no validated mandatory panel.

Qualitative Assessment

  • Joint function: Consistent pain score and predefined activity record.
  • Sleep and tolerability: Sleep disruption, headache, digestive discomfort, bruising, dizziness alongside dose changes.
  • Functional success: Stable or improved strength, activity, and nutrition.